Literature DB >> 20864893

Flumazenil expedites recovery from sevoflurane/remifentanil anaesthesia when administered to healthy unpremedicated patients.

Agathi Karakosta1, Beatrice Andreotti, Chara Chapsa, Aikaterini Pouliou, Emmanouil Anastasiou.   

Abstract

BACKGROUND AND
OBJECTIVE: To investigate the hypothesis that 0.3 mg flumazenil administered to healthy unpremedicated patients at the end of deep surgical sevoflurane/remifentanil anaesthesia would expedite recovery. Flumazenil, an imidazobenzodiazepine derivative, antagonizes the hypnotic/sedative effects of benzodiazepines on γ-aminobutyric acid receptors. However, endogenous benzodiazepine ligands (endozepines) were isolated in mammalian tissues of individuals who had not received benzodiazepines.
METHODS: Twenty-four healthy unpremedicated patients, scheduled to undergo elective surgery requiring general anaesthesia, were randomly allocated to receive either a single dose of 0.3 mg flumazenil (n = 14) or placebo (n = 10) intravenously at the end of the surgical procedure just before the discontinuation of the volatile anaesthetic. After study drug administration, the authors compared various recovery parameters in the flumazenil and control groups.
RESULTS: Median time to spontaneous respiration, eye opening on verbal command, extubation and time to date of birth recollection was significantly shorter in the flumazenil group than in the control group [2.5 min (2.0-3.0) vs. 7.0 min (6.8-8.3), 3.4 min (3.0-4.0) vs. 8.1 min (6.9-10.2), 4.0 min (3.0-5.0) vs. 9.0 min (7.0-10.8) and 4.7 min (4.0-5.0) vs. 10.3 min (8.0-12.0), respectively].
CONCLUSION: Administration of a single dose of 0.3 mg flumazenil to healthy unpremedicated patients at the end of sevoflurane/remifentanil anaesthesia results in earlier emergence from anaesthesia and significantly expedites recovery. This could redefine the role of flumazenil in general anaesthesia, implicating endozepine-dependent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864893     DOI: 10.1097/EJA.0b013e3283398ef9

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  7 in total

1.  Effect of flumazenil on sevoflurane requirements for minimum alveolar anesthetic concentration-awake and recovery status.

Authors:  Peng Liang; Cheng Zhou; Kai-Yu Li; Li-Juan Guo; Bin Liu; Jin Liu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 2.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

3.  Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.

Authors:  Philip W Moore; J Ward Donovan; Keith K Burkhart; Jeffrey A Waskin; Michelle A Hieger; Audrey R Adkins; Yijin Wert; David A Haggerty; J J Rasimas
Journal:  J Med Toxicol       Date:  2014-06

4.  Effects of γ-Aminobutyric Acid Type A Receptor Modulation by Flumazenil on Emergence from General Anesthesia.

Authors:  Seyed A Safavynia; Glenda Keating; Iris Speigel; Jonathan A Fidler; Matthias Kreuzer; David B Rye; Andrew Jenkins; Paul S García
Journal:  Anesthesiology       Date:  2016-07       Impact factor: 7.892

5.  Effect of flumazenil on recovery from anesthesia and the bispectral index after sevoflurane/fentanyl general anesthesia in unpremedicated patients.

Authors:  Yi Jeong Kim; Heeseung Lee; Chi Hyo Kim; Guie Yong Lee; Hee Jung Baik; Jong In Han
Journal:  Korean J Anesthesiol       Date:  2012-01-25

6.  Reversal agents in anaesthesia and critical care.

Authors:  Nibedita Pani; Pradeep A Dongare; Rajeeb Kumar Mishra
Journal:  Indian J Anaesth       Date:  2015-10

7.  [The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes].

Authors:  Troy G Seelhammer; Eric M DeGraff; Travis J Behrens; Justin C Robinson; Kristen L Selleck; Darrell R Schroeder; Juraj Sprung; Toby N Weingarten
Journal:  Braz J Anesthesiol       Date:  2018-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.